دورية أكاديمية
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
| العنوان: | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors. |
|---|---|
| المؤلفون: | Ancel, Julien, Dormoy, Valérian, Raby, Béatrice Nawrocki, Dalstein, Véronique, Durlach, Anne, Dewolf, Maxime, Gilles, Christine, Polette, Myriam, Deslée, Gaëtan |
| المصدر: | Frontiers in Immunology, 14, 1171649 (2023) |
| بيانات النشر: | Frontiers Media S.A., 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | circulating tumor (ctDNA), circulating tumor cell (CTC), immunotherapy, liquid biopsy, neutrophil lymphocyte ratio (NLR), non-small cell lung cancer (NSCLC), soluble biomarkers, Immune Checkpoint Inhibitors, Biomarkers, Tumor, Humans, Immune Checkpoint Inhibitors/therapeutic use, Lymphocytes/metabolism, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/metabolism, Lung Neoplasms/pathology, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymphocytes, Immunology and Allergy, Immunology, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie |
| الوصف: | Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological-driven decision. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/fullTest; urn:issn:1664-3224 |
| DOI: | 10.3389/fimmu.2023.1171649 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/306292Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.306292 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.3389/fimmu.2023.1171649 |
|---|